新型冠状病毒肺炎病人营养中添加谷氨酰胺双肽可行性分析  

Feasibility of adding glutamine dipeptide to nutrition in patients with novel coronavirus pneumonia

作　　者：唐密密 杜洁 罗平 梁宏岩 龚志成[1] 刘韶[1] TANG Mi-mi;DU Jie;LUO Ping;LIANG Hong-yan;GONG Zhi-cheng;LIU Shao(Department of Pharmacy,Xiangya Hospital,Central South University/The Hunan Institute of Pharmacy Practice and Clinical Research/Institute of Hospital Pharmacy,Central South University,Changsha 410008,Hunan,China)

机构地区：[1]中南大学湘雅医院药学部/中南大学医院药学研究所/湖南省临床药学研究中心,湖南长沙410008

出　　处：《肠外与肠内营养》2021年第1期55-59,64,共6页Parenteral & Enteral Nutrition

基　　金：湖南省重点领域专项(NO.2020SK3022)湘财教指[2019]60号。

摘　　要：研究新型冠状病毒肺炎(COVID-19)疫情中,对于感染2019新型冠状病毒(SARS-Co V-2)的病人,是否应该在营养制剂中添加谷氨酰胺双肽。本文通过资料整理、文献回顾,综述了谷氨酰胺双肽的作用,探讨了其对COVID-19的潜在风险和临床获益。得出结论:(1)对于轻中症COVID-19病人,可视病人免疫状态决定是否添加谷氨酰胺。(2)对于COVID-19合并ARDS的病人,若病情稳定且无肝肾功能衰竭,可考虑补充谷氨酰胺。(3)对于重症恢复期的病人,应考虑肠内补充谷氨酰胺。(4)对于儿科病人,目前尚缺乏明确谷氨酰胺补充使病人获益的证据,应谨慎使用。营养制剂中添加谷氨酰胺双肽对COVID-19病人病情的影响需要进一步的临床研究。There has been much concern about whether glutamine dipeptide should be added to nutrition for patients with novel coronavirus pneumonia(COVID-19). We reviewed the effects of glutamine dipeptide on COVID-19, and its potential risks or clinical benefits. For patients with mild to moderate COVID-19, glutamine can be added depending on the immune status. For patients with COVID-19 combined with ARDS, if the condition is stable and without liver or kidney failure, glutamine supplementation is recommended. For patients in convalescence, intestinal supplementation of glutamine is recommended. For pediatric patients, there is no clear evidence whether glutamine supplement benefits patients. Further studies are needed to figure out the effect of glutamine dipeptide on patients with COVID-19.

关 键 词：新型冠状病毒 营养 谷氨酰胺 

分 类 号：R459.3[医药卫生—治疗学] R563.1[医药卫生—临床医学]